According to this recent study, patients who relapse after adjuvant targeted therapy (TT) respond well to subsequent anti-PD-1 based therapy and have outcomes similar to those seen when first line anti-PD-1 therapy is used in stage IV melanoma.
Data of this recent study suggest an interesting correlation between IFN-γ/IL-10 ratio and response to anti-PD-1 therapy in advanced melanoma patients, suggesting a new biomarker that could be easily incorporated in clinical practice.
According to this recent study, pretreatment circulating tumor DNA (ctDNA) is a reliable indicator of patient outcome in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line ICI setting, especially in patients pretreated with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients with high ctDNA may preferentially benefit from combination immunotherapy.
Melanoma New Zealand is looking for two part-time Melanoma Educators with qualifications and experience in dermoscopy. Ideally suited to a Doctor or Registered Nurse, these busy new roles present an exciting opportunity to travel the country in Melanoma New Zealand’s new van providing awareness and education in the community about melanoma prevention as well as providing spot checks to help raise awareness about the importance of regular full skin checks for early detection.
According to this recent study, the use of immunosuppressive steroids for melanoma is associated with worse overall survival. Use of steroids should be limited when possible.
To increase understanding of the genomic landscape of acral melanoma, whole genome sequencing of 87 tumors with matching transcriptome sequencing for 63 tumors was performed in this recent study. Mutational signature analysis reveals a subset of tumors, mostly subungual, with an ultraviolet radiation signature.
One potential problem with the effectiveness of immunotherapies for cancers is the loss of interferon signaling in tumors, which impairs the effectiveness of both immune checkpoint blockade and cell-based therapies. According to this recent study, defective interferon signaling in tumors could be bypassed with the immunostimulatory compound BO-112.
This paper aims to provide an up-to-date overview regarding the current status of regenerative wound dressings for skin cancer therapy. Specifically, the recent discoveries in natural biocompounds as anti-cancer agents for skin cancer treatment and the most intensively studied biomaterials for bioactive wound dressing development will be described.
According to this recent study, KRAS mutations could help identify patients with primary melanoma at higher risk of brain metastases who may benefit from more intensive, protracted surveillance.
According to this recent phase 3 trial, the efficacy, safety and on-treatment biomarker modulations associated with spartalizumab plus dabrafenib and trametinib in the treatment of metastatic melanoma are promising.